MAPT and Alzheimer disease: TMAO, a gut microbiome-produced metabolite previously linked to cardiovascular disease [52], is increased in the cerebrospinal fluid of AD patients and is directly correlated to CSF tau biomarkers, suggesting a role in brain aging and cognitive decline [53].